Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Business Wire
1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent growth versus fourth quarter 2016 Fourth quarter and full year 2017 financial results to be reported Thursday, February 22, 2018 ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited revenue for the fourth quarter and full year 2017. Novocure plans to discuss these results with investors at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. Novocure is a global oncology company developing a proprietary therapy called Tumor Treating Fields for the treatment of solid tumor cancers. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.MarketBeat
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Business Wire
- NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an "overweight" rating on the stock.MarketBeat
- NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
- Novocure to Report First Quarter 2024 Financial ResultsBusiness Wire
NVCR
Earnings
- 2/22/24 - Beat
NVCR
Sec Filings
- 4/12/24 - Form PRE
- 3/27/24 - Form 8-K
- 3/5/24 - Form 4
- NVCR's page on the SEC website